The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series.

Ofatumumab (OFA) is an anti-CD20 antibody. We assessed the therapeutic potential of OFA in five pediatric anti-NMDAR encephalitis patients who showed poor responses to the first-line immunotherapy. OFA treatment showed clinical improvement including alleviation of clinical symptoms and mRS decrease accompanied by anti-NMDAR antibody turning negative in 3 patients and decline in 2 patients. And all patients achieved B cell depletion after OFA treatment. During follow-up, all patients' symptoms were stable. OFA treatment is safe and effective, easy to administer, and favorable for pediatric anti-NMDAE encephalitis patients who are refractory to the first-line immunotherapy.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Xiaojing Li reports financial support was provided by Guangzhou Municipal Science and Technology Basic and Applied Research Project. Wenlin Wu reports financial support was provided by Applied Basic Research Foundation of Guangzhou City. Chi Hou reports financial support was provided by Guangzhou Municipal Science and Technology Basic and Applied Research Project. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Authors. Published by Elsevier Ltd.)